AA Pharma Bromocriptine Indications/Uses

Galactorrhea with or with amenorrhea due to hyperprolactinemia.
Prolactin-dependent menstrual disorders and infertility: e.g. secondary amenorrhea, ovulatory insufficiency and short luteal phase.
Prolactin-secreting adenomas: as a treatment for inoperable macroadenomas or prior to surgery in order to facilitate removal, and as an alternative to surgery in patients with microadenomas.
Prolactin-dependent male hypogonadism.
Acromegaly: the first-line treatment of this condition is by surgery or radiotherapy. AA PHARMA BROMOCRIPTINE (bromocriptine mesylate) may be a useful adjunct to such treatment and can he used as monotherapy in special cases.
Parkinson's Disease: AA PHARMA BROMOCRIPTINE has been found to be clinically useful as an adjunct to levodopa (usually with a decarboxylate inhibitor) in the symptomatic management of selected patients with Parkinson's Disease who experience prominent dyskinesia or wearing off reactions on long-term levodopa therapy.
Patients on long-term treatment who are beginning to deteriorate on levodopa therapy may be controlled by reducing the dose of levodopa and adjusting the frequency and schedule of drug administration. Patients maintained on optimal dosages of levodopa who still experience prominent dyskinesia and/or end-of-dose failure may benefit from the concomitant use of bromocriptine, by decreasing the occurrence and/or severity of these manifestations. Since rapid escalation of bromocriptine doses causes severe adverse reactions, it is usually recommended to combine a slow increase of bromocriptine, with a concomitant, gradual and limited reduction of levodopa dosage. Continued efficacy of bromocriptine for more than two years has not been established and there is some evidence that its efficacy tends to wane. Evidence available indicates that there is no consistent benefit from bromocriptine in patients who have not responded previously to levodopa, and studies have shown significantly more adverse reactions in bromocriptine treated patients than in patients treated with levodopa. AA PHARMA BROMOCRIPTINE is not recommended in the treatment of newly diagnosed patients or as the sole medication in Parkinson's Disease.